베팅·게임 | Cases & Studies in Betting & Gaming | 赌博 & 投机
- date : 2015-05-20 01:10|hit : 2623
-
- Article] Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers
-
DocNo of ILP: 414
Doc. Type: Article
Title: Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers
Authors: Smart, K; Desmond, RC; Poulos, CX; Zack, M
Full Name of Authors: Smart, Kelly; Desmond, Renee C.; Poulos, Constantine X.; Zack, Martin
Keywords by Author: Modafinil; Pathological gambling; Dopamine; Reward; Salience
Keywords Plus: PLACEBO-CONTROLLED TRIAL; GAMBLING BEHAVIOR; DECISION-MAKING; DOUBLE-BLIND; DOPAMINE; DISORDERS; HYPERSENSITIVITY; METHYLPHENIDATE; COMORBIDITY; DEPRESSION
Abstract: This study examined the effects of modafinil (200 mg) on slot machine betting profiles from a previous sample of low and high impulsivity (LI/HI) pathological gamblers (10/Group; Zack and Poulos, 2009). Hierarchical regression assessed the prospective relationship between Payoff and Bet Size on consecutive trials, along with moderating effects of Group, Cumulative Winnings (low/high) and Phase of game (early/late) under drug and placebo. Y intercepts for the simple regressions of Bet Size on Payoff indexed overall motivation to bet. Under placebo, both groups gauged their bets less closely to the preceding Payoff as trials continued when Winnings were low but not high. Under modafinil, both groups gauged their bets more closely to the preceding Payoff when Winnings were low but gauged their bets less closely to the previous Payoff when Winnings were high. The tendency to gauge bets closely to the previous Payoff coincided with a bias toward low overall Bet Size, and modafinil accentuated this relationship, in LI but not HI subjects. Results suggest that modafinil increases the salience of environmental rewards, leading to more tightly calibrated responses to individual rewards when resources are low, but progressively loosens reward-response calibration when resources are high. Increased relative impact of phasic vs. tonic dopamine signals may account for patterns seen at low vs. high Winnings, respectively, under the drug. Clinically, modafinil may deter pathological gamblers from chasing losses but also encourage them to continue betting rather than quit while they are ahead. Whether low-dose modafinil confers more uniform benefits deserves investigation. (C) 2013 Elsevier Ltd. All rights reserved.
Cate of OECD: Basic medicine
Year of Publication: 2013
Business Area: game
Detail Business: game
Country: England
Study Area: terminal, slot machine, gambler, dopamine, drug, depression
Name of Journal: NEUROPHARMACOLOGY
Language: English
Country of Authors: [Smart, Kelly; Desmond, Renee C.; Zack, Martin] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; [Smart, Kelly; Zack, Martin] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada; [Poulos, Constantine X.] Univ Toronto, Dept Psychol, Toronto, ON M5S 3G3, Canada
Press Adress: Zack, M (reprint author), Ctr Addict & Mental Hlth, 33 Russell St, Toronto, ON M5S 2S1, Canada.
Email Address: martin.zack@camh.ca
Citaion:
Funding: Ontario Problem Gambling Research Centre
Lists of Citation: Bakken IJ, 2009, SCAND J PSYCHOL, V50, P333, DOI 10.1111/j.1467-9450.2009.00713.x; Beaudoin CM, 1999, CAN J PSYCHIAT, V44, P483; Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x; Clark L, 2009, NEURON, V61, P481, DOI 10.1016/j.neuron.2008.12.031; Dackis CA, 2005, NEUROPSYCHOPHARMACOL, V30, P205, DOI 10.1038/sj.npp.1300600; Dannon PN, 2005, J CLIN PSYCHOPHARM, V25, P593, DOI 10.1097/01.jcp.0000186867.90289.ed; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; de Wit H, 2000, BEHAV NEUROSCI, V114, P830, DOI 10.1037//0735-7044.114.4.830; Di Russo F, 2000, J PSYCHIAT RES, V34, P75, DOI 10.1016/S0022-3956(99)00030-8; Dixon MJ, 2010, ADDICTION, V105, P1819, DOI 10.1111/j.1360-0443.2010.03050.x; El-Guebaly N, 2006, J GAMBL STUD, V22, P275, DOI 10.1007/s10899-006-9016-6; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P613, DOI 10.1016/0191-8869(85)90011-X; Gamo NJ, 2010, J AM ACAD CHILD PSY, V49, P1011, DOI 10.1016/j.jaac.2010.06.015; Goudriaan AE, 2008, PSYCHOL MED, V38, P41, DOI 10.1017/S0033291707000694; Grall-Bronnec M, 2012, J GAMBL STUD, V28, P239, DOI 10.1007/s10899-011-9258-9; Grant J.E., 2012, BR J CLIN PHARM, DOI DOI 10.1111/J.1365-2125.2012.04457.X.[EPUB; Grant JE, 2010, PSYCHOPHARMACOLOGY, V212, P603, DOI 10.1007/s00213-010-1994-5; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50; Hewig J, 2010, BIOL PSYCHIAT, V67, P781, DOI 10.1016/j.biopsych.2009.11.009; Hikosaka O, 2008, CURR OPIN NEUROBIOL, V18, P203, DOI 10.1016/j.conb.2008.07.002; Hodgins DC, 2012, PSYCHOL MED, V42, P2433, DOI 10.1017/S0033291712000724; Kahbazi M, 2009, PSYCHIAT RES, V168, P234, DOI 10.1016/j.psychres.2008.06.024; Kalechstein AD, 2007, J NEUROPSYCH CLIN N, V19, P298, DOI 10.1176/appi.neuropsych.19.3.298; LESIEUR HR, 1987, AM J PSYCHIAT, V144, P1184; McNichol D, 1972, PRIMER SIGNAL DETECT; Minzenberg MJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1477, DOI 10.1038/sj.npp.1301534; Muller CA, 2011, PHARMACOPSYCHIATRY, V44, P81, DOI 10.1055/s-0031-1271683; Niv Y, 2007, PSYCHOPHARMACOLOGY, V191, P507, DOI 10.1007/s00213-006-0502-4; Niv Yael, 2007, Ann N Y Acad Sci, V1104, P357, DOI 10.1196/annals.1390.018; Oberg SAK, 2011, NEUROPSYCHOLOGIA, V49, P3768, DOI 10.1016/j.neuropsychologia.2011.09.037; Paterson NE, 2010, PHARMACOL BIOCHEM BE, V95, P449, DOI 10.1016/j.pbb.2010.03.006; Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051; Petry NM, 2005, J CLIN PSYCHIAT, V66, P564; Petry NM, 2003, ADDICTION, V98, P645, DOI 10.1046/j.1360-0443.2003.00336.x; Robbins TW, 2007, PSYCHOPHARMACOLOGY, V191, P433, DOI 10.1007/s00213-006-0528-7; Robertson P, 2003, CLIN PHARMACOKINET, V42, P123, DOI 10.2165/00003088-200342020-00002; Saez-Abad C, 2008, J ADDICT DIS, V27, P33, DOI 10.1300/J069v27n01_04; Shao R, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.10; SKINNER HA, 1982, J ABNORM PSYCHOL, V91, P199, DOI 10.1037//0021-843X.91.3.199; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41; Sofuoglu M, 2012, NEUROPHARMACOLOGY, V64, P452; Spencer RC, 2012, BIOL PSYCHIAT, V72, P221, DOI 10.1016/j.biopsych.2011.12.002; Stoops WW, 2005, PSYCHOPHARMACOLOGY, V182, P186, DOI 10.1007/s00213-005-0044-1; Sugam JA, 2012, BIOL PSYCHIAT, V71, P199, DOI 10.1016/j.biopsych.2011.09.029; Tremblay AM, 2011, ADDICT BIOL, V16, P467, DOI 10.1111/j.1369-1600.2010.00208.x; Turner N. E., 2005, INT GAMBLING STUDIES, V5, P95, DOI DOI 10.1080/14459790500098044; Volkow ND, 2009, JAMA-J AM MED ASSOC, V301, P1148, DOI 10.1001/jama.2009.351; Volkow ND, 2005, BIOL PSYCHIAT, V57, P1410, DOI 10.1016/j.biopsych.2004.11.006; Zack M, 2009, J PSYCHOPHARMACOL, V23, P660, DOI 10.1177/0269881108091072
Number of Citaion: 50
Publication: PERGAMON-ELSEVIER SCIENCE LTD
City of Publication: OXFORD
Address of Publication: THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
ISSN: 0028-3908
29-Character Source Abbreviation: NEUROPHARMACOLOGY
ISO Source Abbreviation: Neuropharmacology
Volume: 73
Version:
Start of File: 66
End of File: 74
DOI: 10.1016/j.neuropharm.2013.05.015
Number of Pages: 9
Web of Science Category: Neurosciences; Pharmacology & Pharmacy
Subject Category: Neurosciences & Neurology; Pharmacology & Pharmacy
Document Delivery Number: 229AD
Unique Article Identifier: WOS:000325233300008
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 14:37:45 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next